Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 1/20 | 0.66 |
| ▸ | KDM1A | O60341 | 12/20 | 0.62 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.62 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.62 |
| ▸ | PRNP | P04156 | 1/20 | 0.62 |
| ▸ | TP53 | P04637 | 1/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.62 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.62 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.62 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.62 |
| ▸ | HTR1A | P08908 | 1/20 | 0.62 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.62 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.62 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.62 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.62 |
| ▸ | DRD2 | P14416 | 1/20 | 0.62 |
| ▸ | TSHR | P16473 | 1/20 | 0.62 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.62 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.62 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30950674 | 0.94 | PIM1 (0.69) | PIM1KDM1ASIGMAR1SLC22A1PRNP | |
| SCHEMBL30950671 | 0.94 | PIM1 (0.69) | PIM1KDM1ASIGMAR1SLC22A1PRNP | |
| SCHEMBL30950675 | 0.93 | PIM1 (0.67) | PIM1KDM1ASIGMAR1SLC22A1PRNP | |
| SCHEMBL16616978 | 0.93 | PIM1 (0.67) | PIM1KDM1ASIGMAR1SLC22A1PRNP | |
| SCHEMBL11402576 | 0.93 | PIM1 (0.67) | PIM1KDM1ASIGMAR1SLC22A1PRNP | |
| SCHEMBL29947142 | 0.88 | KDM1A (0.59) | PIM1KDM1ASIGMAR1SLC22A1PRNP | |
| SCHEMBL6858868 | 0.86 | CYP2D6 (0.70) | KDM1ASIGMAR1SLC22A1PRNPTP53 | |
| SCHEMBL30934895 | 0.86 | CYP2D6 (0.70) | KDM1ASIGMAR1SLC22A1PRNPTP53 | |
| SCHEMBL208025 | 0.86 | PIM1 (0.79) | PIM1KDM1ASIGMAR1SLC22A1PRNP | |
| SCHEMBL17298325 | 0.83 | HTR2A (0.44) | PIM1KDM1ASIGMAR1SLC22A1PRNP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12594264-B2 | Modulators of alpha-synuclein proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2026-04-07 | — | — | US | disclosed |
| US-20240091204-A1 | MODULATORS OF ALPHA-SYNUCLEIN PROTEOLYSIS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2024-03-21 | — | — | US | disclosed |
| US-11707452-B2 | Modulators of alpha-synuclein proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2023-07-25 | — | — | US | disclosed |
| US-11707452-B2 | Modulators of alpha-synuclein proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2023-07-25 | — | — | US | disclosed |
| US-11707452-B2 | Modulators of alpha-synuclein proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2023-07-25 | — | — | US | disclosed |
| EP-3841100-A1 | PROTEOLYSIS TARGETING CHIMERIC (PROTAC) COMPOUND WITH E3 UBIQUITIN LIGASE BINDING ACTIVITY AND TARGETING ALPHA-SYNUCLEIN PROTEIN FOR TREATING NEURODEGENERATIVE DISEASES | Arvinas Operations, Inc. (US) | 2021-06-30 | — | — | EP | disclosed |
| CN-112912376-A | Proteolytic targeted chimeric (PROTAC) compounds with E3 ubiquitin ligase binding activity and targeting alpha-synuclein for the treatment of neurodegenerative diseases | 阿尔维纳斯运营股份有限公司 | 2021-06-04 | — | — | CN | disclosed |
| US-20200085793-A1 | MODULATORS OF ALPHA-SYNUCLEIN PROTEOLYSIS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2020-03-19 | — | — | US | disclosed |
| WO-2020041331-A1 | PROTEOLYSIS TARGETING CHIMERIC (PROTAC) COMPOUND WITH E3 UBIQUITIN LIGASE BINDING ACTIVITY AND TARGETING ALPHA-SYNUCLEIN PROTEIN FOR TREATING NEURODEGENERATIVE DISEASES | ARVINAS OPERATIONS, INC. (US) | 2020-02-27 | — | — | WO | disclosed |
| WO-2020041331-A1 | PROTEOLYSIS TARGETING CHIMERIC (PROTAC) COMPOUND WITH E3 UBIQUITIN LIGASE BINDING ACTIVITY AND TARGETING ALPHA-SYNUCLEIN PROTEIN FOR TREATING NEURODEGENERATIVE DISEASES | ARVINAS OPERATIONS, INC. (US) | 2020-02-27 | — | — | WO | disclosed |
| US-20080081329-A1 | Electrochemical Detection of Substrates | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2008-04-03 | — | — | US | disclosed |
| US-5929247-A | METHODS OF SYNTHESIZING 1,2,5-THIADIAZOLE COMPOUNDS SUCH AS 3-PROPYLTHIO-4-HYDROXY-1,2,5-THIADIAZOLE, USEFUL IN TREATING DISEASES IN THE CENTRAL NERVOUS SYSTEM CAUSED BY MUSCARINIC CHOLINERGIC SYSTEM MALFUNCTIONING | ELI LILLY AND COMPANY (US) | 1999-07-27 | — | — | US | disclosed |
| US-5852037-A | Method for treating anxiety | ELI LILLY AND COMPANY (US) | 1998-12-22 | — | — | US | disclosed |
| US-5821370-A | MUSCARINIC CHOLINERGIC DRUGS | ELI LILLY AND COMPANY (US) | 1998-10-13 | — | — | US | disclosed |
| US-5821371-A | 1,2,5-THIADIAZOLE COMPOUNDS USEFUL IN THE TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM CAUSED BY MALFUNCTIONING OF THE MUSCARINIC CHOLINERGIC SYSTEM; COGNITION ACTIVATORS; ALZHEIMER'S DISEASE | ELI LILLY AND COMANY (US) | 1998-10-13 | — | — | US | disclosed |
| US-5672709-A | INTERMEDIATES FOR DRUGS USEFUL IN TREATING CENTRAL NERVOUS SYSTEM DISORDERS | ELI LILLY AND COMPANY (US) | 1997-09-30 | — | — | US | disclosed |
| US-5665745-A | 1,2,5-THIADIAZOLE DERIVATIVES FOR TREATING DISEASES OF CENTRAL NERVOUS SYSTEM | ELI LILLY AND COMPANY (US) | 1997-09-09 | — | — | US | disclosed |
| US-5646289-A | REACTING A 3-CHLORO-1,2,5-THIADIAZOLE WITH ALKALI METAL BIS(TRIALKYL OR ARYLSILYL)AMIDE; DECHLORINATION; TREATING NERVOUS SYSTEM DISORDERS | ELI LILLY AND COMPANY (US) | 1997-07-08 | — | — | US | disclosed |
| EP-0774256-A1 | Use of azacyclic or azabicyclic thiadiazole compounds for treating anxiety | ELI LILLY AND COMPANY (US) | 1997-05-21 | — | — | EP | disclosed |
| EP-0709381-A1 | Heterocyclic compounds and their preparation and use | ELI LILLY AND COMPANY (US) | 1996-05-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240091204-A1 | MODULATORS OF ALPHA-SYNUCLEIN PROTEOLYSIS AND ASSOCIATED METHODS OF USE | UCHL1, ADRM1, CRBN | PIM1 2261/4885KDM1A 2282/4885SIGMAR1 2774/4885 |
| US-20200085793-A1 | MODULATORS OF ALPHA-SYNUCLEIN PROTEOLYSIS AND ASSOCIATED METHODS OF USE | UCHL1, ADRM1, CRBN | PIM1 2261/4885KDM1A 2282/4885SIGMAR1 2774/4885 |
| US-12594264-B2 | Modulators of alpha-synuclein proteolysis and associated methods of use | ADRM1, CRBN, SNCA | PIM1 2372/4885KDM1A 1518/4885SIGMAR1 1102/4885 |
| US-11707452-B2 | Modulators of alpha-synuclein proteolysis and associated methods of use | UCHL1, ADRM1, CRBN | PIM1 2261/4885KDM1A 2282/4885SIGMAR1 2774/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.